Thomas E. Mürdter

4.4k citations

109 papers · 3.2k indexed · h-index 31

Impact in

Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
- Inflammatory mediators and NSAID effects
Oncology top 5%
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis

Papers in ⓘ

Pharmacology 34
- Pharmacogenetics and Drug Metabolism 33
- Inflammatory mediators and NSAID effects 13
Oncology 31
- Cancer Treatment and Pharmacology 8
- Drug Transport and Resistance Mechanisms 8

Co-authors: Matthias Schwab (48 shared papers)Michel Eichelbaum (17 shared papers)Georg Heinkele (15 shared papers)Ulrich M. Zanger (13 shared papers)Péter Fritz (22 shared papers)Hiltrud Brauch (17 shared papers)Ute Hofmann (16 shared papers)Reinhold Kerb (7 shared papers)
Journals: Clinical Pharmacology & Therapeutics (5 papers)Analytical and Bioanalytical Chemistry (4 papers)Cancers (3 papers)Cancer Research (3 papers)Naunyn-Schmiedeberg s Archives of Pharmacology (3 papers)
Partner nations: Germany United States Australia

In The Last Decade

Thomas E. Mürdter

107 papers receiving 3.2k citations

Peers

Countries citing papers authored by Thomas E. Mürdter

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Mürdter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Mürdter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Mürdter more than expected).

Fields of papers citing papers by Thomas E. Mürdter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Mürdter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Mürdter. The network helps show where Thomas E. Mürdter may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas E. Mürdter, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas E. Mürdter Line = papers co-authored together Thomas E. Mürdter links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 109 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy Annals of Surgical Oncology ·Wiebke Solaß, Reinhold Kerb, Thomas E. Mürdter, Urs Giger-Pabst, Dirk Strumberg, Clemens Tempfer, Jürgen Zieren, Matthias Schwab, Marc A. Reymond	2013	271
2	Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine Journal of Pharmacology and Experimental Therapeutics ·Tanja Richter, Thomas E. Mürdter, Georg Heinkele, Jürgen Pleiss, Stephan Tatzel, Matthias Schwab, Michel Eichelbaum, Ulrich M. Zanger	2004	204
3	Fate of the Antibiotic Sulfamethoxazole and Its Two Major Human Metabolites in a Water Sediment Test Environmental Science & Technology ·Michael Radke, Christoph Lauwigi, Georg Heinkele, Thomas E. Mürdter, Marion Letzel	2009	190
4	P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans Clinical Pharmacology & Therapeutics ·Siegfried Drescher, Hartmut Glaeser, Thomas E. Mürdter, Monika Hitzl, Michel Eichelbaum, Martin F. Fromm	2003	120
5	Pharmacogenomics of Tamoxifen Therapy Clinical Chemistry ·Hiltrud Brauch, Thomas E. Mürdter, Michel Eichelbaum, Matthias Schwab	2009	113
6	The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z‐4‐hydroxy‐tamoxifen in human liver British Journal of Clinical Pharmacology ·Janet K. Coller, Niels Krebsfaenger, Kathrin Klein, Karin Endrizzi, Renzo Wolbold, Thomas Lang, Andreas K. Nüssler, P. Neuhaus, Ulrich M. Zanger, Michel Eichelbaum, Thomas E. Mürdter	2002	106
7	Role of P-Glycoprotein Inhibition for Drug Interactions Clinical Pharmacokinetics ·Sonja Eberl, Bertold Renner, Antje Neubert, Mareike Reisig, Iouri Bachmakov, Jörg König, Frank Dörje, Thomas E. Mürdter, Andreas Ackermann, Harald Dormann, Karl G Gassmann, Eckhart G. Hahn, Stefanie Zierhut, Kay Brune, Martin F. Fromm	2007	88
8	Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment BMC Cancer ·Heiko van der Kuip, Thomas E. Mürdter, Maike Sonnenberg, Monika McClellan, Susanne Gutzeit, Andreas Gerteis, Wolfgang Simon, Péter Fritz, Walter E. Aulitzky	2006	85
9	Expression and function of β-glucuronidase in pancreatic cancer: potential role in drug targeting Naunyn-Schmiedeberg s Archives of Pharmacology ·Bernhard Sperker, Ulrike Werner, Thomas E. Mürdter, Ceren Tekkaya, Péter Fritz, R. Wacke, Ulrich Adam, Manfred Gerken, Bernd Drewelow, Heyo K. Kroemer	2000	72
10	Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters Journal of Clinical Oncology ·Hiltrud Brauch, Werner Schroth, Matthew P. Goetz, Thomas E. Mürdter, Stefan Winter, James N. Ingle, Matthias Schwab, Michel Eichelbaum	2012	70
11	Genetic polymorphisms of glutathione S‐transferase A1, the major glutathione S‐transferase in human liver: Consequences for enzyme expression and busulfan conjugation Clinical Pharmacology & Therapeutics ·Monika Bredschneider, Kathrin Klein, Thomas E. Mürdter, Claudia Marx, Michel Eichelbaum, Andreas K. Nüssler, P. Neuhaus, Ulrich M. Zanger, Matthias Schwab	2002	65
12	Influence of Age and Cytochrome P450 2C9 Genotype on the Steady-State Disposition of Diclofenac and Celecoxib Clinical Pharmacokinetics ·Stefanie S. Brenner, Charlotte Herrlinger, Karin Dilger, Thomas E. Mürdter, Ute Hofmann, Claudia Marx, Ulrich Klotz	2003	64
13	Dasatinib reverses Cancer-associated Fibroblasts (CAFs) from primary Lung Carcinomas to a Phenotype comparable to that of normal Fibroblasts Molecular Cancer ·Silke Haubeiß, Jens O. Schmid, Thomas E. Mürdter, Maike Sonnenberg, Godehard Friedel, Heiko van der Kuip, Walter E. Aulitzky	2010	62
14	Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. PubMed ·Thomas E. Mürdter, Bernhard Sperker, K T Kivistö, Monika McClellan, Péter Fritz, Godehard Friedel, A. Linder, Klaus Bosslet, H. Toomes, R Dierkesmann, H K Kroemer	1997	61
15	Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest Cancer Research ·Lea Schaaf, Matthias Schwab, Christoph Ulmer, Simon Heine, Thomas E. Mürdter, Jens O. Schmid, Georg Sauer, Walter E. Aulitzky, Heiko van der Kuip	2016	60
16	The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells European Journal of Pharmaceutics and Biopharmaceutics ·Sebastian Taetz, Noha Nafee, Julia Beisner, Kamilla Piotrowska, Christiane Baldes, Thomas E. Mürdter, Hanno Huwer, Marc Schneider, Ulrich F. Schaefer, Ulrich Klotz	2008	52
17	Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast BMC Cancer ·Maike Sonnenberg, Heiko van der Kuip, Silke Haubeiß, Péter Fritz, Werner Schroth, Godehard Friedel, Wolfgang Simon, Thomas E. Mürdter, Walter E. Aulitzky	2008	52
18	Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen Frontiers in Pharmacology ·Werner Schroth, Stefan Winter, Thomas E. Mürdter, Elke Schaeffeler, Diana Eccles, Bryony Eccles, Balram Chowbay, Chiea Chuen Khor, Arafat Tfayli, Nathalie K. Zgheib, Michel Eichelbaum, Matthias Schwab, Hiltrud Brauch	2017	47
19	Dose Optimization of a Doxorubicin Prodrug (HMR 1826) in Isolated Perfused Human Lungs: Low Tumor pH Promotes Prodrug Activation by β-Glucuronidase Journal of Pharmacology and Experimental Therapeutics ·Thomas E. Mürdter, Godehard Friedel, Janne T. Backman, Monika McClellan, Monika Schick, Manfred Gerken, Klaus Bosslet, Péter Fritz, H. Toomes, Heyo K. Kroemer, Bernhard Sperker	2002	46
20	Distribution of Microsomal Epoxide Hydrolase in Humans: An Immunohistochemical Study in Normal Tissues, and Benign and Malignant Tumours The Histochemical Journal ·Janet K. Coller, Péter Fritz, Ulrich M. Zanger, Isabel Siegle, Michel Eichelbaum, Heyo K. Kroemer, Thomas E. Mürdter	2001	45

About Thomas E. Mürdter

Thomas E. Mürdter is a scholar working on Pharmacology, Oncology, Genetics, Pharmaceutical Science and Cancer Research, having authored 109 papers that have together received 3.2k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (33 papers), Estrogen and related hormone effects (28 papers), Inflammatory mediators and NSAID effects (13 papers), RNA Interference and Gene Delivery (10 papers), Cancer, Hypoxia, and Metabolism (9 papers), Cancer Treatment and Pharmacology (8 papers), Advanced biosensing and bioanalysis techniques (8 papers) and Drug Transport and Resistance Mechanisms (8 papers). The work is most often cited by research in Pharmacology (845 citations), Oncology (926 citations), Pharmacology (389 citations), Pharmaceutical Science (110 citations) and Reproductive Medicine (148 citations). Thomas E. Mürdter has collaborated with scholars based in Germany, United States and Australia. Frequent co-authors include Matthias Schwab, Michel Eichelbaum, Georg Heinkele, Ulrich M. Zanger, Péter Fritz, Hiltrud Brauch, Ute Hofmann, Reinhold Kerb, Godehard Friedel and Ulrich Klotz. Their work appears in journals such as Clinical Pharmacology & Therapeutics, Analytical and Bioanalytical Chemistry, Cancers, Cancer Research and Naunyn-Schmiedeberg s Archives of Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact